from 10 different blood group systems could be identified in 126 patients (1.5%) due to the genotype information obtained for the reagent RBCs. Antibodies to antigens from the Knops system (53 patients; 42%, 8 patients with anti-Kn b ) and to Cartwright antigens (31 patients; 25%) were the most frequent. Conclusion: The use of genotyped reagent RBCs in antibody identification panels extends the range of detectable antibody specificities, accelerates the antibody identification, and improves the pre-transfusion diagnostics.
Introduction
Since 1900 more than 350 red blood cell (RBC) antigens have been discovered. They are defined serologically by the use of a specific antibody. Antigens receiving ISBT numbers (assigned by the ISBT Working Party on Red Cell Immunogenetics and Blood Group Nomenclature) must have been shown to be inherited characters [1, 2] . All antigens fall into one of the following classifications: systems, collections (200 series), low-incidence antigens (700 series), and high-incidence antigens (901 series). A blood group system consists of one or more antigens controlled at a single gene locus, or by two or more very closely linked homologous genes with little or no observable recombination between them (table 1) . Collections consist of serologically, biochemically, or genetically related antigens, which do not fit the criteria required for system Keywords Pre-transfusion diagnostics · Molecular blood typing · Antibody identification
Summary

Background:
The detection and identification of antibodies to red blood cell (RBC) antigens is one of the most important and challenging issues in transfusion medicine. Up to date there are 354 RBC antigens recognized by the International Society of Blood Transfusion (ISBT). The reagent RBCs used in commercial antibody screening and identification panels however are usually serologically typed for up to 40 clinically important antigens. Thus the identification of many antibody specificities remains impossible when using reagent RBCs with only limited information about their antigens. To improve the pre-transfusion diagnostics, we developed antibody identification panels with reagent RBCs serologically typed for 26 antigens and additionally genotyped for 30 blood group alleles. Methods: The reagent RBCs in the panels were characterized serologically for the clinically most significant 'standard' antigens. The reagent RBC donors were additionally genotyped by using in-house PCR-SSP methods. The antibody identification was performed in the indirect antiglobulin test using untreated and papain-treated RBCs in the gel technique. Antibodies identified due to the genotype information were confirmed by serology using appropriate reference RBCs. Results: Within a time period of 3 years and 8 months, 16,878 blood samples from 8,467 patients were tested in our reference laboratory. In total, 21 different antibodies status (table 2) . The 700 series contains antigens with an incidence of less than 1% and which cannot be included in a system or collection. The 901 series contains antigens with an incidence of greater than 90% and which cannot be included in a system or collection (table 2) .
The most important parts of the pre-transfusion diagnostics are the ABO typing and the screening for clinically significant irregular (unexpected) antibodies in blood recipients. The national Guidelines in Germany ('Richtlinie zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten') recommend reagent RBC phenotyping for at least 19 antigens (C, C The knowledge of the genetic background of a blood group antigen is the prerequisite for the development and use of genotyping methods [3] . Nowadays almost every blood group antigen can be typed by analysis of a corresponding DNA marker. Most blood group antigens differ from their antithetic partner by the alteration of a single nucleotide in the DNA sequence of the blood group gene. By genotyping of these single nucleotide polymorphisms (SNPs), the blood group phenotype can reliably be derived. Usually, genotyping methods are based on the polymerase chain reaction (PCR) with the use of genomic DNA. The large variety of techniques that were developed during the last two decades differs generally in the type of chemistry for specific detection of the SNP alleles [4] [5] [6] [7] . Among the first methods that were developed, the PCR with sequence-specific primers (PCR-SSP) was the most common. PCR-SSP is a very cost-effective and robust method especially for the analysis of a limited number of SNPs in single or a low number of samples.
This progress in molecular immunohematology significantly contributes to optimized blood supply of patients and to prevention of immunization to blood cell antigens [8] . To improve the pre-transfusion diagnostics we developed antibody identification panels with reagent RBCs serologically typed for 26 'standard' antigens and additionally genotyped for 30 blood group alleles. We demonstrate that the use of these panels in routine testing significantly improves the pre-transfusion diagnostics, extending the range of detectable antibody specificities. 
Material and Methods
Test Cell Panels
The reagent RBCs in the panels were tested serologically with licensed test sera for the following clinically most significant 'standard' antigens: RhD, C, c, E, e, C w , K, k, Kp (table 3) were typed by using in-house PCR-SSP methods according to a previously published standard protocol ( fig. 1) [9] . C w -positive donors were genotyped for the C w allele (RHCE*02.08) in order to identify RHCE*02.08 homozygous individuals who are negative for the MAR (RH51) antigen [10] . For that purpose a specific TaqMan TM PCR assay with primers (forward: TTTTTACCCACTATGACGCTTCCTT; reverse: CTGTTCCAAT-GAACTCTCACCTTGA) and fluorescently labeled minor groove binding probes (for C w : FAM-CCCTTTCGATCCTC; for non-C w : VIC-CCCCTTTT-GATCCTC) was used according to the standard protocol of the manufacturer (Life Technologies, Darmstadt, Germany). Among 1,506 donors who had been previously phenotyped C w -positive on the blood group analyzer Backman Coulter PK7200 we identified 25 donors homozygous for the RHCE*02.08 allele.
The antibody screening and identification were performed in the indirect antiglobulin test using untreated and papain-treated RBCs in the gel technique (Gel cards of BioRad, Cressier, Switzerland; and Grifols, Barcelona, Spain). Antibodies identified due to the genotype information were confirmed by serology using appropriate reference RBCs.
Results
The genotyped reagent RBC panels were introduced for routine use in our reference laboratory in August 2014. Over a time period of 3 years and 8 months, 16,878 samples from 8,467 patients were analyzed. In 234 blood samples (1.4%) derived from 126 patients (1.5%), the genotype information obtained for the test cells led to the identification and specification of an antibody (table 4) . Overall, 21 different antibody specificities against antigens from 10 different blood group systems were identified. Antibodies to antigens from the Knops system (KN) were the most frequent (53 of 126 patients; 42%), followed by antibodies to the Cartwright antigens (31 of 126 patients; 25%).
Some of the patients were repeatedly tested because of multiple transfusions or for control testing during a pregnancy. In all these cases the re-identification of the antibody was possible and could be performed in a short time. Three example cases (anti-Do a + anti-E, anti-Au b + anti-Lu a , and anti-MAR) that were tested in our laboratory are demonstrated in figures 2-4.
Discussion
To improve the pre-transfusion diagnostics, we developed antibody identification panels with reagent RBCs serologically typed for 26 'standard' antigens and additionally genotyped for 30 blood group alleles. The use of these panels led to the identification of antibody specificities difficult to obtain with standard commercial panels. In our patient population 1.5% of the cases contained such antibodies.
The most frequent specificities (42%) were antibodies to the Knops antigens Kn a , Yk a , Kn b and KCAM. Unexpectedly we found anti-Kn b in 28 samples of 8 different patients. It had been reported only once in the literature [11] but now seems to be quite a common antibody. We also identified 6 patients with anti-KCAM which was reported in 2 cases only [12] . Interestingly, we found neither anti- antibodies could be inhibited by the specific recombinant blood group proteins which are commercially available now (Imusyn, Hannover, Germany). In combination with the genotyped reagent RBCs this emerging serological technique is a very helpful tool in antibody diagnostics. It is especially valuable to identify antibodies to high-frequency antigens and to exclude or identify additional antibodies in patients who have antibodies to high-frequency antigens. However the recombinant blood group proteins are available for a limited number of specificities. So far they could not be synthetized for proteins with many transmembrane parts like Rhesus, Diego, or Colton. With few exceptions, the recombinant blood group proteins do not inhibit antibodies to low frequency. We also found single patients with the rare antibody specificities anti-Wu (DI9) and antiTar (RH40) which is present on red cells with RhD VII .
Anti-MAR-(like) has not been reported in Germany before. Now, we could identify two patients with alloanti-MAR-(like). MAR (RH51) is a high-prevalence Rh antigen which is potentially clinically significant. Only individuals who are combined heterozygous for RhC w and C x (RhC w C x ) or homozygous for RhC w or RhC x , or who are Rh null or RhD-, are MAR-(like)-negative. The original MAR-negative individual (RhC w C x ) was found in Finland [13] . Our studies revealed that in our donor population in Southwestern Germany only one of 19,000 blood donors is MAR-negative. One of the patients with anti-MAR had an additional anti-S and received compatible blood from MAR-negative and S-negative donors we had found in our previous donor screening.
The clear identification of the antibody specificities is essential to estimate the risk of possible hemolytic transfusion reactions, especially when antibodies to high-frequency antigens are present and serologically incompatible transfusions are necessary. Thus the genotyping of the test RBCs improves the quality of the test reagents and overcomes the limitations of the serological typing caused by shortage and a limited number of licensed test sera. The use of genotyped test cells in antibody identification panels extends the range of detectable antibody specificities, accelerates the antibody identification, and improves the pre-transfusion diagnostics.
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